GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Prescott Group Capital Management L.L.C.

Key Points

• Prescott Group Capital Management L.L.C. reduced its stake in GoodRx Holdings, Inc. by 40.6%, now holding 80,000 shares valued at approximately $353,000 as per recent SEC filings.
• Several institutional investors increased their positions in GoodRx, with the National Bank of Canada FI raising its stake by 34.9% recently, indicating significant interest from the investment community.
• Analysts have lowered their price targets for GoodRx with a consensus price target of $6.55 and a rating of "Moderate Buy," reflecting a cautious outlook amid mixed earnings reports.

Prescott Group Capital Management L.L.C. lessened its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 40.6% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 80,000 shares of the company's stock after selling 54,660 shares during the period. Prescott Group Capital Management L.L.C.'s holdings in GoodRx were worth $353,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in GoodRx during the first quarter valued at about $274,000. Allianz Asset Management GmbH grew its holdings in GoodRx by 20.3% during the first quarter. Allianz Asset Management GmbH now owns 278,077 shares of the company's stock valued at $1,226,000 after purchasing an additional 46,900 shares during the period. SBI Securities Co. Ltd. grew its holdings in GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after purchasing an additional 2,748 shares during the period. Hohimer Wealth Management LLC grew its holdings in GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after purchasing an additional 2,658 shares during the period. Finally, Teacher Retirement System of Texas bought a new position in shares of GoodRx in the first quarter worth about $218,000. Institutional investors own 63.77% of the company's stock.

GoodRx Trading Down 2.1%

Shares of NASDAQ GDRX traded down $0.11 during midday trading on Tuesday, hitting $4.91. The company's stock had a trading volume of 413,464 shares, compared to its average volume of 1,439,245. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.74. The business's 50 day moving average is $4.51 and its two-hundred day moving average is $4.56. GoodRx Holdings, Inc. has a 12-month low of $3.67 and a 12-month high of $9.16. The firm has a market cap of $1.75 billion, a P/E ratio of 61.32, a price-to-earnings-growth ratio of 2.22 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a return on equity of 7.85% and a net margin of 3.57%. The firm had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. During the same period in the prior year, the business posted $0.08 earnings per share. The company's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

GDRX has been the subject of a number of recent analyst reports. Wells Fargo & Company dropped their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Truist Financial dropped their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Finally, UBS Group dropped their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, GoodRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.55.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.53% of the stock is currently owned by company insiders.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.